Prevalence of Neurological Symptoms Associated with COVID-19

Abstract

The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected millions of individuals worldwide, leading to a broad spectrum of clinical manifestations. While primarily known for respiratory symptoms, emerging evidence suggests that COVID-19 can also have neurological implications. Understanding the prevalence and nature of neurological symptoms associated with the disease is crucial for effective management and resource allocation. Objective: To better understand the prevalence of neurological symptoms associated with COVID-19. Several factors such as age, gender, and comorbidity are explored to create a more holistic understanding of the impact of COVID-19. Methods: After meeting inclusion and exclusion criteria, 111 patients admitted to Ibne Sina Hospital were recruited between October 2021 and February 2022. A descriptive statistical analysis was conducted to summarize patients most often encountered signs and symptoms concerning the above parameters. Results: Out of 111 patients, a significant proportion of symptoms occurred in patients aged 40-60 years, with Dysgeusia being the most widespread (75.5%), followed by Encephalitis (45.9%), GBS (28.8%), Encephalopathy (18.9%), and Ischemic Stroke (6.3%). These were most prevalent in hypertensive individuals (46%) and Diabetes Mellitus (31%). In asthmatic individuals, they are the least prevalent (10.8%). Conclusions: Despite the predominance of neurological manifestations, the present scientific literature cannot demonstrate a definitive causal association between the symptoms and the virus. This study carefully ensures a link age, gender, and comorbidity along with the prevalence of neurological manifestations of COVID-19. For a comprehensive treatment plan, a holistic understanding of symptoms is critical.